How we investigate drug-induced immune hemolytic anemia by Leger, Regina M. et al.
IMMUNOHEMATOLOGY, Volume 30, Number 2, 2014 85
How we investigate drug-induced immune 
hemolytic anemia
R.M. Leger, P.A. Arndt, and G. Garratty
Drugs are a rare cause of immune hemolytic anemia, but an 
investigation for a drug antibody may be warranted if a patient 
has definitive evidence of immune hemolysis, other more common 
causes of hemolysis have been excluded, and there is a good 
temporal relationship between the administration of a drug and 
the hemolytic event. Drug antibodies are either drug-dependent 
(require drug to be in the test system) or drug-independent 
(reactive without drug present in the test). Drug-dependent 
antibodies are investigated by testing drug-treated red blood cells 
(RBCs) or by testing RBCs in the presence of a solution of drug. 
Drug-independent antibodies are serologically indistinct from 
idiopathic warm autoantibodies and cannot be defined or ex-
cluded by serologic testing. Nonimmunologic protein adsorption, 
caused by some drugs, is independent of antibody production but 
may also cause immune hemolytic anemia. Serologic methods for 
testing for drug antibodies are presented, and observations from 
more than 30 years of this laboratory’s experience are discussed. 
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Dr. Garratty’s Immunohematology Research Laboratory 
at the American Red Cross in Southern California has 
investigated drug-induced immune hemolytic anemia (DIIHA) 
for 35 years. When contacted to investigate a possible DIIHA, 
we ask a series of questions:
• Does the patient have hemolytic anemia (e.g., decreased 
hemoglobin or hematocrit, increased reticulocytes, 
increased indirect bilirubin and lactate dehydrogenase, 
decreased haptoglobin)?
• Does the patient have a positive direct antiglobulin 
test (DAT)? Is there IgG or C3 or both present on the 
patient’s red blood cells (RBCs)? The DAT is used to 
establish an immune etiology for a hemolytic anemia. 
For DIIHA the DAT should be positive for IgG or C3 (or 
both) close to the time of the observed hemolysis. If not 
tested until weeks later, the DAT may be weak or even 
negative, especially if the patient has been transfused 
with multiple RBC units.1
• Was an eluate tested and what were the results? The 
typical prompt for pursuing DIIHA in a patient with 
hemolytic anemia is a positive DAT and nonreactive 
eluate. Some recent findings, however, show that an 
eluate may be reactive while the patient is still receiving 
the drug (e.g., piperacillin, cefotetan).
• What drug(s) is (are) the patient taking now or recently? 
Have any been implicated in causing DIIHA? It is 
important to obtain a complete medication history with 
dates of administration. This includes antibiotics the 
patient may have received for a surgery in the previous 
2 to 3 weeks; such medications might only appear 
on the surgical record and not on a listing of current 
medications.
And most importantly:
• Is there a temporal relationship between the drug 
administration and the hemolytic anemia? If the 
hemolysis began before the drug was administered, then 
there is no temporal relationship. In some situations, 
there may not be any prior administration of the drug 
in question (e.g., cefotetan), while in others, the patient 
may have received the drug previously without any 
obvious adverse effects (ceftriaxone, piperacillin).
In summary, because DIIHA is rare, the time and effort 
of an investigation should only be undertaken when the 
patient has definite evidence of a hemolytic anemia and a good 
temporal relationship to treatment with a particular drug 
exists. When this has been established, the clinician should 
consider stopping the drug, and specimens should be collected 
for an investigation.
The approach and methods described in this article have 
been used in our laboratory for several decades.2 Additional 
information gleaned from our experience is added here.
Types of Drug-Induced Antibodies
There are two types of drug-induced antibodies: drug-
dependent and drug-independent. Serologically, we can only 
determine the presence of drug-dependent antibodies. Drug-
dependent antibodies are subdivided into those that react with 
drug-treated RBCs (e.g., antibodies to penicillin and some 
cephalosporins) and those that react with untreated RBCs 
in the presence of a solution of the drug (e.g., antibodies to 
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ceftriaxone and quinine). Some drug-dependent antibodies 
react both with drug-treated RBCs and in the presence of 
a soluble drug; others react by only one of these methods. 
Drug-independent antibodies (e.g., autoantibodies induced 
by methyldopa and fludarabine) have serologic reactivity 
without the drug being present and are indistinguishable from 
idiopathic IgG warm autoantibodies.
Nonimmunologic Protein Adsorption
Some drugs modify the RBC membrane and cause 
nonimmunologic adsorption of protein (NIPA), resulting 
in positive direct and indirect antiglobulin tests.3 NIPA is 
independent of antibody production, but may be a cause of 
hemolytic anemia.4 Drugs that cause NIPA include some 
cephalosporins, platinum-based chemotherapies (cisplatin, 
carboplatin, and oxaliplatin), and β-lactamase inhibitors 
(clavulanic acid, sulbactam, and tazobactam). NIPA should be 
suspected when a patient’s plasma or serum and most normal 
plasma or sera react in an indirect antiglobulin test with 
drug-treated RBCs, but the eluate from the patient’s RBCs is 
nonreactive with the drug-treated cells. When testing RBCs 
treated with a drug known to cause NIPA, the patient’s serum 
and the controls (negative and positive) are tested both undiluted 
(for detection of a hemolysin or a directly agglutinating drug 
antibody) and at a dilution of 1 in 20 (to avoid NIPA in the 
antiglobulin test). Normal sera diluted 1 in 20 generally do not 
contain enough protein for NIPA to be detected.
To verify that NIPA has occurred, we test the patient’s 
RBCs (DAT) or the drug-treated RBCs after incubation with 
plasma (indirect antiglobulin test) using antihuman albumin 
(Sigma-Aldrich, St. Louis, MO).5 The antihuman albumin is 
not licensed for RBC indirect antiglobulin testing, so it must 
be standardized for this purpose. To determine the appropriate 
dilution of antihuman albumin, doubling dilutions prepared in 
phosphate-buffered saline (PBS) are tested against untreated 
and cephalothin-treated RBCs after incubation at 37°C with 
normal plasma.5 The amount of protein that adsorbs to the 
RBCs increases with time (e.g., 2 hours vs. 30 minutes). When 
new dilutions of antihuman albumin are prepared, expected 
reactivity with cephalothin-treated and -untreated RBCs 
(after incubation with normal plasma) is verified.
Sample From Patient
We request at a minimum 5 mL of EDTA whole blood 
and one or two 10-mL clot tubes (serum is required to detect 
hemolysis or complement activation, e.g., for testing in the 
presence of a soluble drug). It is preferable to have a sample 
from when in vivo hemolysis was first observed. If the patient’s 
serum or plasma appears to have an autoantibody, it is also 
beneficial to have a sample collected 2 to 3 days after the drug 
was stopped. This second sample helps to determine whether 
the observed autoantibody reactivity is truly autoantibody 
or caused by a drug antibody reacting with a circulating 
drug present in the sample obtained while the patient is still 
receiving the drug. This apparent autoantibody is observed 
quite often with antibodies to piperacillin. Once the drug has 
cleared from the patient’s circulation (e.g., about 1–2 days after 
the drug is stopped), this apparent autoantibody reactivity 
disappears, whereas true autoantibody would persist.
Initial immunohematology testing should be completed 
before beginning drug studies. The presence or absence of 
alloantibodies and autoantibodies and eluate results will 
guide the selection of RBCs used for the drug studies and the 
methods to be used. Autoantibodies will need to be removed 
by adsorption before performing tests for drug antibodies for 
the same reason they are removed by adsorption to detect the 
presence of other alloantibodies.
We prepare eluates from the patient’s EDTA RBCs using 
a rapid acid elution kit (e.g., Gamma Elu-Kit II, Immucor, 
Norcross, GA). To wash the RBCs in preparation for the 
elution, we substitute cold (4°C) low-ionic strength saline 
for the kit wash solution. In 1995, we showed that washing 
RBCs with the low-ionic kit wash solution can result in false-
positive eluates when high-titer antibodies are present.6 Cold 
PBS can also be substituted but may be less efficient for lower 
affinity antibodies. The original study on false-positive eluates 
began with detection of anti-D in the eluate from D– RBCs 
after adsorption with a polyclonal anti-D. Coincidental to that 
research, anti-cefotetan was detected in acid eluates prepared 
from maternal and cord RBCs that were collected many 
weeks after the mother received cefotetan. In retrospect, we 
realized that these eluates (prepared using the low-ionic kit 
wash solution) probably gave false-positive results because 
of nonspecific adsorption of high-titer anti-cefotetan to the 
RBCs during the washing for the eluate preparation. This was 
later confirmed with in vitro studies when the mother’s anti-
cefotetan was adsorbed and eluted from untreated RBCs when 
the kit wash solution was used but not when cold PBS was 
used.6
Sample of Drug
We also request a sample of the drug under investigation 
unless we already have it on hand (e.g., powder [1-g vial], 
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tablets, or capsules [2–4]; the drug should not be dissolved 
before sending). We have not been successful using drugs in 
a pediatric oral suspension formula because they hemolyze 
RBCs.5,7
Although it would seem important to use the particular 
drug that a patient received, it is optimal to use pure drug 
rather than a commercial tablet, capsule, or suspension 
product. These commercial formulations contain inert ingre-
dients that can make it difficult to dissolve the drug and test 
with RBCs. It is also possible that antibodies detected in drug 
studies are directed against one of these inert ingredients 
rather than the drug itself.8 Initial testing can be performed 
with the particular drug the patient received, but positive 
results should be confirmed using pure drug to ensure correct 
interpretation. Drugs administered by intravenous injection 
are free of excipients. Some pure drugs are available from 
chemical companies (e.g., Sigma-Aldrich).
Some drugs are combinations of two drugs (e.g., 
Zosyn is a combination of piperacillin plus tazobactam). 
Tazobactam causes NIPA, which can create a problem with 
the interpretation of results, so it is preferable to test with the 
separate components.
Test Methods
If the suspected drug has previously been reported as a 
cause for DIIHA (see tables in Garratty and Arndt9), it is best 
to follow the techniques used in the relevant report. If the drug 
has never been reported or sufficient serologic details are not 
provided, testing the patient’s serum and an eluate from the 
patient’s RBCs against drug-treated RBCs and testing the 
patient’s serum against untreated and enzyme-treated RBCs 
in the presence of the soluble drug is recommended. Many 
more drug antibodies are detected by testing in the presence of 
soluble drug than by testing drug-treated RBCs (see Table 1 in 
Garratty and Arndt9).
We perform all our DIIHA investigations in tubes. Salama 
et al.10 described using the gel test for detecting drug antibodies. 
We have done limited testing in the presence of soluble drug by 
the gel test (ID-Micro Typing System, Pompano Beach, FL) 
using buffered gel and anti-IgG, -C3d gel cards and comparing 
the results with tube tests. Anti-ceftriaxone could be identified 
by the gel test for 9 of 11 examples tested; the presence of anti-
ceftriaxone could not be discerned for two examples. Some 
agglutination and hemolysis detected by tube test was not 
detected by the gel test, and some antiglobulin tests with the 
PBS substituted for the drug were stronger by gel test (e.g., 2+ 
by gel vs. negative or ½+ by tube test).11
Preparing Drug Solutions
The solution of drug must be isotonic for use with RBCs. 
Dissolving drugs in PBS, pH 7.1 to 7.4, is the preferred method. 
Some drugs are readily soluble in PBS, others are somewhat 
soluble, and still others are insoluble. The Merck Index is an 
excellent source for looking up the solubility of a drug.12 For 
drugs that are somewhat soluble, we incubate the solution at 
37°C for about 10 to 15 minutes and mix vigorously on a vortex 
mixer; the solution is then centrifuged, and the supernatant is 
transferred to a clean tube. Even if the drug is not completely 
soluble, sufficient drug may be present for an antibody to be 
detected. Tablets can be crushed using a mortar and pestle, 
taking care to tease apart and remove as much of the outer 
coating as possible. Drug or inert ingredients that are not 
dissolved can damage the RBCs used in the test, so efforts to 
remove particulate matter or find a better medium for solution 
are needed. Drugs that are insoluble in PBS are problematic. 
A lower pH or solvent (e.g., alcohol) may be helpful, but the 
solution would need to be diluted in PBS for an appropriate 
pH and isotonicity to be used with RBCs. Drugs that are 
supplied as an aqueous solution may also need to be diluted in 
PBS before adding to RBCs. Dissolving drugs in an albumin 
solution has been suggested,13 but we have found that 6 percent 
albumin decreases the binding of some drugs (e.g., cefotetan, 
cephalothin) to RBCs.14 Thus, albumin should only be used 
if the drug is insoluble in water and PBS; perhaps 1 percent 
albumin in PBS, as used in drug-induced thrombocytopenia 
investigations, would be a better alternative than 6 percent 
albumin.15
Some drugs are not stable in solution. We have found 
that anti-cefotetan titers were dramatically reduced when the 
solution of cefotetan was just 2 hours old compared with tests 




RBCs, group O Fresh, <7 days old Fresh, <7 days old
Amount of drug 600 mg 400 mg




Volume buffer 15 mL 10 mL




Time of incubation 1 hour 1 hour
RBCs = red blood cells.
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with a fresh solution for both 40 and 1 mg/mL preparations. 
Unless the stability of a particular drug in solution has been 
verified by reproducible titers over time, these solutions need 
to be used as soon as possible after preparation both for 
treating RBCs and for testing in the presence of the drug. We 
have found 1 mg/mL solutions of ceftriaxone in PBS to be 
stable up to 5 days11 and piperacillin to be stable up to 1 week 
(unpublished observations) when stored at 4°C.
Preparing Drug-Treated RBCs
For preparing most drug-treated RBCs, we start with a 
drug concentration of 40 mg/mL in PBS. This concentration 
originated from early studies for optimally preparing penicillin- 
and cephalothin-treated RBCs.16 It is interesting to note one 
cannot make penicillin-coated RBCs with the concentration of 
drug found in vivo (Garratty, unpublished data).
Optimal binding of penicillin G to RBCs occurs with 600 
mg of penicillin G in 15 mL of high-pH buffer (40 mg/mL), 
such as barbital, 0.1 M (pH 9.6–9.8) incubated with 1 mL of 
RBCs at room temperature for 1 hour.16,17 After treating, the 
RBCs are washed three to four times with PBS or until no 
hemolysis is visible. Increased hemolysis can occur if treating 
is extended beyond 1 hour.
Cephalosporin-treated RBCs are prepared slightly 
differently: 400 mg of the drug is dissolved in 10 mL of PBS, 
pH 7.3 (for 40 mg/mL), and incubated with 1 mL of RBCs at 
37°C for 1 hour.2 So 40 mg/mL of drug is used but at a 10:1 
ratio of drug solution to RBCs (vs. 15:1 for penicillin). Also, 
binding of cephalosporins is greater at 37°C than at room 
temperature (the opposite of penicillin).16 Originally, pH 10.0 
buffer was used to prepare cephalosporin-treated RBCs, but a 
high pH is not required for optimal coating.16 In fact, a lower 
pH (e.g., pH 6–7) decreases NIPA that occurs when some 
cephalosporin- and other drug-treated RBCs are incubated 
with plasma or serum (i.e., during testing).18,19 When testing a 
drug that we have not previously tested or for which there is no 
previous report, we typically use the cephalosporin treatment 
method, unless the drug is in the penicillin family. The 
preparation of penicillin-treated and cephalosporin-treated 
RBCs is compared in Table 1.
Some drugs require a different buffer (e.g., borate for 
nafcillin20,21) or incubation at 4°C (e.g., for erythromycin7,22). 
Occasionally, a drug is only available in aqueous solution at a 
lower concentration or contains an ingredient that damages 
RBCs (e.g., hemolysis) during treatment. This takes a trial and 
error approach, testing different concentrations, temperatures, 
and time of treatment incubation. Chemotherapeutic drugs in 
aqueous solution, such as oxaliplatin and carboplatin, have 
been successfully used at 1 or 5 mg/mL in PBS, respectively, 
to treat RBCs. Cimetidine, which was supplied as an aqueous 
solution containing alcohol, hemolyzed RBCs when prepared 
at 40 mg/mL at both 37°C and room temperature, but was used 
successfully at 15 mg/mL in PBS with a room temperature 
treatment incubation.23
For whatever method is used, another aliquot of RBCs is 
prepared under the same conditions in the appropriate buffer 
or PBS (without the drug) to serve as the control untreated 
RBCs. These untreated RBCs are tested in parallel with the 
drug-treated RBCs. The volume of drug-treated and untreated 
RBCs prepared can be scaled down as long as the appropriate 
ratio is kept constant (e.g., dissolving 100 mg of cephalosporin 
in 2.5 mL of PBS and adding 0.25 mL of packed RBCs 
maintains the 40 mg/mL concentration with a 10:1 ratio).
Some drug-treated (e.g., penicillin, cephalothin, cefotetan) 
and untreated control RBCs can be stored for a short time 
(a few days) at 4°C, with Alsever’s solution added; however, 
reactivity of treated RBCs will weaken over time. These RBCs 
can also be stored frozen in liquid nitrogen. Other drug-treated 
RBCs might not store well. For example, cimetidine-treated 
RBCs were nonreactive after storage overnight at 4°C.23
Testing Drug-Treated RBCs
Drug-treated RBCs are tested in parallel with the control 
untreated RBCs by tube test. Two sets of tubes are labeled for 
each sample to be tested. For the patient, serum (or plasma) 
and an eluate and last wash are tested. Negative controls 
include normal sera or plasma (pooled or several individual 
sera) and PBS. A positive control is tested whenever available. 
If the drug under investigation is known to cause NIPA, the 
patient’s serum and the normal sera or plasma are also tested 
at a dilution of 1 in 20, and the positive control is tested at a 
dilution of 1 in 20 or greater.
Two drops of each sample and control are tested with one 
drop of the drug-treated or control untreated RBCs (3–5% 
suspension in PBS). The tubes are incubated at 37°C for 1 hour 
and then centrifuged and examined for hemolysis (if serum 
was tested) and agglutination. The RBCs are washed four times 
with PBS, two drops of antihuman globulin are added, and the 
tubes are centrifuged and examined for agglutination. If the 
patient’s plasma is tested, testing with anti-IgG is sufficient; 
if patient’s serum is tested, we use polyspecific antihuman 
globulin to also detect complement activation.
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Interpretation of Results
Test results with drug-treated RBCs are often 
straightforward. Results definitive for a drug antibody are 
(1) reactivity of the patient’s serum and eluate with the drug-
treated RBCs and no reactivity with the untreated RBCs, (2) 
no reactivity of the normal sera or plasma and PBS controls, 
and (3) reactivity of the positive control, if available, with 
only the drug-treated RBCs (see expected results for a drug 
antibody that reacts with drug-treated RBCs in Table 2). 
Reactivity can be hemolysis, direct agglutination, or a positive 
indirect antiglobulin test, or a combination of these results. In 
cases of DIIHA caused by high-dose intravenous penicillin, 
the anti-penicillin is detectable in an eluate prepared from 
the patient’s RBCs. Theoretically, this should be true for other 
drug antibodies reactive with drug-treated RBCs, but eluates 
in these cases have not always been reactive.
For some drugs (e.g., cefotetan, oxaliplatin), the results can 
be confusing and potentially misleading unless the appropriate 
controls described previously are included. Table 3 shows the 
interpretation of various results with drug-treated RBCs.
No reactivity of the patient’s serum and eluate together 
with a positive result for the positive control indicates the 
absence of a drug antibody. No reactivity of the patient’s 
serum and eluate without a positive control, however, does not 
exclude a drug antibody and can only be interpreted that the 
drug antibody was not detected; without a positive control, 
it is unknown whether the drug was truly bound to the test 
RBCs. The report must state that a positive control was not 
tested. No reactivity of the patient’s serum and eluate and no 
reactivity of the positive control is an invalid test; there may be 
no drug bound to those RBCs or the positive control may have 
deteriorated.
Reactivity of the patient’s serum and eluate with both the 
drug-treated and untreated RBCs indicates the presence of 
alloantibody, autoantibody, or circulating drug or drug–anti-
drug complexes. Additional work is required. If an alloantibody 
is present, new drug-treated RBCs that are negative for the 
appropriate antigen(s) need to be tested. If autoantibody is 
Table 2. Expected results when drug antibody reacts with drug-
treated RBCs
Drug-treated RBCs Untreated RBCs
Sample tested
60 min at 
37°C AHG
60 min at 
37°C AHG
Patient’s serum +/0 + 0 0
Patient’s serum diluted 1 in 20* +/0 + 0 0
Eluate +/0 + 0 0
Last wash 0 0 0 0
Normal sera (pooled or 4–6 
individuals)
0 0/+* 0 0
Normal sera diluted 1 in 20* 0 0 0 0
Positive control +/0 + 0 0
PBS 0 0 0 0
*If drug causes nonimmunologic protein adsorption, normal sera will react at 
the antiglobulin test; a 1 in 20 dilution should not react.
AHG = antihuman globulin; PBS = phosphate-buffered saline; RBCs = red 
blood cells.
Table 3. Interpretation of tests with drug-treated RBCs
Drug-treated RBCs Untreated RBCs
Patient’s serum
Patient’s 
serum 1/20 Eluate Last wash Normal sera/plasma
Normal sera/
plasma 1/20 PBS Positive control Patient’s serum Interpretation
+ NT + 0 0 NT 0 + 0 Drug antibody
+ + + 0 + 0 0 + 0 Drug antibody
+ NT + 0 0 NT 0 NA 0 Drug antibody
0 NT 0 0 0 NT 0 + 0 No drug antibody detected
0 NT 0 0 0 NT 0 NA 0 No drug antibody detected; 
?drug bound to RBCs; no 
positive control
+ (AGT only) 0 0 0 + (AGT only) 0 0 + at ≥1/20* 0 NIPA but no drug antibody 
detected
+ direct aggl, 
+ or 0 AGT
0 0 0 with some sera, + direct 
aggl, + or 0 AGT
0 0 + 0 Not DIIHA; environmental 
exposure?
+ NT + /0 0 0 NT 0 + + Alloantibody? Autoantibody? 
Drug–anti-drug? needs 
additional testing
*When NIPA occurs, the positive control should be shown to react at dilution ≥1 in 20.
RBCs = red blood cells; PBS = phosphate-buffered saline; NT = not tested; NA = not available; AGT = antiglobulin test; NIPA = nonimmunologic protein 
adsorption; aggl = agglutination; DIIHA = drug-induced immune hemolytic anemia.
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present, the serum can be adsorbed and retested. Circulating 
drug or drug–anti-drug complexes will also be removed by 
adsorption. Alternatively, the patient’s serum can be dialyzed 
to remove circulating drug. If the reactivity is caused by 
circulating drug or drug–anti-drug complexes, the reactivity 
should disappear after the patient is no longer receiving the 
drug and the drug has cleared from the circulation.
If the normal sera or plasma reacts with the drug-treated 
RBCs but does not react with the untreated RBCs, there are two 
likely explanations. First, if the reactivity is at the antiglobulin 
phase only, the reactivity is probably attributable to NIPA. 
Several individual sera should be retested both undiluted and 
diluted 1 in 20; the 1 in 20 dilution should be nonreactive (the 
protein content should be too low to be a problem). For drugs 
that cause NIPA, most or all normal sera will react with the 
drug-treated RBCs; however, the strength can vary from weak 
to strong among sera.
If the normal sera or plasma causes direct agglutination of 
the drug-treated RBCs, but not the untreated RBCs, a low-titer 
antibody to the drug could be present. Antibodies to several 
drugs (e.g., penicillin, cephalothin, cefotetan, piperacillin, 
meropenem, oxaliplatin) have been detected in plasma from 
blood donors and patients who do not have hemolytic anemia.24 
Widespread use of antibiotics in agriculture and environmental 
contamination have been suggested as the source of exposure to 
many drugs.25,26 Most of these antibodies are IgM and low titer, 
but occasionally these antibodies react in sera diluted greater 
than 1 in 20, especially anti-cefotetan. This agglutination can 
be anywhere from 1+ to 4+ in strength. The presence of these 
antibodies in the plasma of healthy individuals underscores 
the importance of testing normal sera or plasma against drug-
treated RBCs. It is imperative that the presence of a drug 
antibody should not be determined on the basis of a single test 
of undiluted patient’s plasma without sufficient normal sera 
or plasma (either pooled or several individual sera) tested in 
parallel. Anti-cefotetan found in normal sera has reacted up 
to a dilution of 1 in 100, so in tests against cefotetan-treated 
RBCs, the patient’s plasma should be strongly reactive, at least 
at a dilution of 1/100 for identification of anti-cefotetan as a 
cause of DIIHA (unpublished observations). Titration of the 
patient’s plasma against drug-treated RBCs, in parallel with 
normal sera, may help to distinguish a low-titer antibody 
in normal sera from a high-titer antibody that is causing 
hemolysis (see subsequent discussion).
Even though piperacillin is a semisynthetic penicillin, 
we do not recommend testing piperacillin-treated RBCs 
because plasma from a high percentage of blood donors 
(91%) and patients (49%) directly agglutinated piperacillin-
coated RBCs.25 In contrast to cefotetan antibodies, piperacillin 
antibodies in patients with DIIHA do not react to high titers 
with piperacillin-treated RBCs (unpublished observations). 
Thus, testing in the presence of a soluble drug is more reliable 
for detecting clinically significant antibodies to piperacillin.
Hapten Inhibition to Prove Specificity
If positive results for a drug antibody are obtained when 
testing drug-treated RBCs without a positive control or no 
previous report, we would attempt hapten inhibition to prove 
the specificity of the antibody. Inhibition of reactivity occurs 
when the antibody has combined with the hapten of the same 
specificity as the subsequently added antigen. Dilutions of the 
patient’s serum incubated with different concentrations of the 
drug are tested against the drug-treated RBCs. Alternatively, a 
dilution of the patient’s serum that reacts 2+ can be selected for 
testing with different concentrations of drug. For example, two 
drops of plasma are incubated with two drops of drug solution 
(10 mg/mL, 1 mg/mL, and 0.1 mg/mL) for 60 minutes at 
37°C for the inhibition phase. The control against which the 
inhibition tests are compared is two drops of plasma plus two 
drops of PBS (substituted for the drug). One drop of 3 to 5 
percent drug-treated RBCs is added after the inhibition phase 
and incubated for 60 minutes at 37°C. Inhibition by the soluble 
drug is shown by a weaker reaction (partial inhibition) or no 
reaction (complete inhibition) with the drug-treated RBCs. As 
shown in Table 4, a solution of oxaliplatin added to the plasma 
inhibited direct agglutination of oxaliplatin-treated RBCs, 
thus proving the specificity of the antibody. In this example, 
the antibody reactivity of the 1 in 2 dilution of plasma was 
too strong (3½+ with the PBS control) to be inhibited until 
R.M. Leger et al.
Table 4. Inhibition test: reactivity of plasma (diluted) plus solution 
of oxaliplatin or PBS versus oxaliplatin-treated red blood cells
Solution added
Plasma #1 
1 in 2 dilution
Plasma #1 






Interpretation Partial inhibition with 5 
mg/mL of drug; proof 
of specificity of anti-
oxaliplatin would have 
been missed if only tested 
with 1 mg/mL of drug
Complete inhibition with 5 
mg/mL of drug and partial 
inhibition with 2.5 and 1 
mg/mL of drug
PBS = phosphate-buffered saline; s = strong.
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the higher concentration of drug (5 mg/mL) was added for 
the inhibition; when the serum was diluted further so that the 
PBS control yielded a 2+ reaction, the inhibition was clear even 
with the lower 1 mg/mL concentration. If the serum plus drug 
reacts more strongly than the respective dilution of serum 
plus PBS control, then the drug antibody works preferentially 
when testing untreated RBCs in the presence of drug. Drug 
antibodies that react only by testing in the presence of a 
solution of drug (e.g., ceftriaxone) should not be inhibited. IgG 
antibodies are more difficult to inhibit than IgM antibodies of 
the same titer.27 Drugs with a common chemical core might 
demonstrate cross-reactivity in hapten inhibition tests (e.g., 
some anti-piperacillin can be inhibited by penicillin).25
Testing in the Presence of Soluble Drug
Antibodies to many drugs are detected by testing untreated 
RBCs in the presence of a solution of the drug. Piperacillin and 
some of the second- and third-generation cephalosporins react 
by this method; anti-ceftriaxone has been detected only by 
testing in the presence of drug.
For testing a patient’s sample in the presence of soluble 
drug, we prepare a 1 mg/mL solution of the drug in PBS. 
For example, 10 mg of powder, capsule contents, or crushed 
tablet are dissolved in 10 mL of PBS. As described above, if 
the drug is not completely dissolved, the solution is centrifuged 
and the supernate is transferred to a clean tube. The drug 
solution should be approximately pH 7 to be compatible with 
RBCs (i.e., adjusted to pH 6–8, if necessary). The 1 mg/mL 
concentration used for testing in the presence of soluble drug 
has no correlation to the therapeutic in vivo concentration of 
the drug. However, this concentration has been successfully 
used for decades to detect most drug antibodies.
Patient’s serum is incubated in the presence of the soluble 
drug, with and without the addition of fresh normal serum 
as a source of complement, and tested with untreated and 
enzyme-treated RBCs (see details in Table 5). Serum, rather 
than plasma, is the preferred specimen for this testing for the 
observation of hemolysis; this also allows for the addition of 
fresh normal serum as a source of complement. Testing with 
enzyme-treated RBCs and the addition of a complement source 
may increase the sensitivity of the test, especially for hemolysis. 
Pooled RBCs (e.g., R1R1 and R2R2 RBCs) are prepared at a 
heavier concentration (6 to 10 percent); an aliquot of these 
RBCs are enzyme-treated. The heavier RBC suspension 
enhances detection of hemolysis. Because of the heavier RBC 
suspension, more thorough washing for the antiglobulin test 
may be accomplished if performed manually rather than using 
an automated cell washer. Antigen-negative RBCs are selected 
if alloantibodies are present. If autoantibodies are present, the 
serum is adsorbed with allogeneic RBCs before testing (any 
alloantibodies can also be adsorbed out).
The complement source is serum from two or more 
individuals, screened for reactivity with enzyme-treated RBCs, 
pooled, aliquoted, and frozen at –55°C or less on the same day 
that it was collected.28 To show that the complement source 
has hemolytic ability, the complement source is added to serum 
containing a hemolytic antibody (e.g., anti-I) that has been 
inactivated by incubation at 56°C for 30 minutes (if necessary) 
and tested with antigen-positive RBCs. Complement source 
prepared in this manner can be stored at –55°C or less for 
1 year.
Interpretation of Results
Hemolysis, agglutination, or positive indirect antiglobulin 
tests may occur together or separately. The expected results for 
a positive test for drug antibody are reactivity in the tests with 
patient’s serum plus drug and no reactivity in the respective 
control tests of patient’s serum plus PBS or the tests with 
complement source but no patient’s serum. The tests with 
serum plus PBS serve as controls for the respective tests with 
serum plus drug solution (see Table 6). No reactivity in any of 
the tests indicates no drug antibody is present.
There are times when results are not so straightforward 
(see Table 7). The PBS control test(s) may be reactive. This can 
be because of autoantibody, alloantibody, or circulating drug 
or drug–anti-drug complexes. A positive result in the test with 
drug and a significantly weaker result in the corresponding 
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Table 5. Testing in the presence of a drug solution
1. Label two sets of tubes for untreated and enzyme-treated RBCs:
• Serum + drug
• Serum + PBS
• Serum + complement + drug
• Serum + complement + PBS
• Complement + drug
• Complement + PBS
• Positive control (if available) + drug*
• Positive control (if available) + PBS
2. Place 2 drops of serum, complement source, drug, and PBS in the 
appropriate tubes
3. Add 1 drop of untreated or enzyme-treated RBCs (6–10% suspension)
4. Mix and incubate at 37°C for 1 hour
5. Centrifuge and examine for hemolysis and agglutination
6. Wash RBCs four times and add polyspecific antihuman globulin; 
examine for agglutination
7. Add IgG-coated RBCs to nonreactive tests
*Positive control need not be tested with both untreated and enzyme-treated 
RBCs.
RBCs = red blood cells; PBS = phosphate-buffered saline.
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test with PBS indicate drug antibody is present. Equivalent 
reactivity of patient’s serum in both the drug and PBS tests 
may be caused by alloantibody or autoantibody. Adsorbing 
the serum to remove alloantibody or autoantibody and drug 
or drug–anti-drug complexes, or dialyzing the serum to 
remove circulating drug, may resolve the problem. If the 
reactivity is caused by circulating drug or drug–anti-drug 
complexes, the reactivity should disappear after the patient is 
no longer receiving the drug and the drug has cleared from 
the circulation. For piperacillin, ceftriaxone, and cefotetan, the 
reactivity should disappear about 1 to 2 days after the drug is 
stopped; other drugs may have a longer elimination half-life.
The addition of fresh normal serum (complement) can 
sometimes enhance agglutination of a drug antibody tested 
against enzyme-treated RBCs. This phenomenon is not 
completely understood. For one patient who probably had 
a circulating drug that resulted in positive antiglobulin tests 
in the PBS controls, direct agglutination of enzyme-treated 
RBCs in the presence of ceftriaxone plus fresh normal serum 
(complement source) provided the distinguishing reactivity for 
a ceftriaxone antibody.11 The controls of complement plus drug 
and complement plus PBS should be negative; the complement 
plus drug test ensures the complement source by itself does 
not cause complement activation in the presence of the drug 
or react with the test RBCs (with or without drug). If the 
complement plus drug test is positive at the antiglobulin test 
and the complement plus PBS test is negative, NIPA may be 
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Table 6. Expected results when drug antibody reacts in the 
presence of a soluble drug
Untreated RBCs Enzyme-treated RBCs
Sample tested
60 min at 
37°C AHG
60 min at 
37°C AHG
Patient’s serum + drug +/0 +/0 + +
Patient’s serum + PBS 0 0 0 0
Patient’s serum + C + drug +/0 +/0 +/H +
Patient’s serum + C + PBS 0 0 0 0
Positive control + drug +/0 +/0 + +
Positive control + PBS 0 0 0 0
C + drug 0 0 0 0
C + PBS 0 0 0 0
RBCs = red blood cells; AHG = antihuman globulin; PBS = phosphate-
buffered saline; C = complement source; H = hemolysis.
Table 7. Interpretation of various example tests in the presence of a soluble drug
Untreated RBCs Enzyme-treated RBCs
Test 37°C AHG 37°C AHG Interpretation
Patient’s serum + drug 0 0 3+ 1+ Positive (drug antibody)
Patient’s serum + PBS 0 0 0 0
Patient’s serum + C + drug 0 0 4+ 1+
Patient’s serum + C + PBS 0 0 0 0
Patient’s serum + drug 2+H/3+ 3+ 4+H — Positive (drug antibody)
Patient’s serum + PBS 0 0 0 0
Patient’s serum + C + drug 2+H/3+ 3+ 4+H —
Patient’s serum + C + PBS 0 0 0 0
Patient’s serum + drug 0 1+s 4+ 3+ Positive (drug antibody) and circulating drug or drug–anti-drug complexes
Patient’s serum + PBS 0 m+ ± 1+
Patient’s serum + C + drug 0 1+ 4+ 2+
Patient’s serum + C + PBS 0 0 1+ ±
Patient’s serum + drug 3+s 2+ 2+H/4+ 4+ Positive (drug antibody) and circulating drug or drug–anti-drug complexes
Patient’s serum + PBS 0 0 3+ 1+
Patient’s serum + C + drug 2+s 2+ 2+H/4+ 4+
Patient’s serum + C + PBS 0 0 3+ 1+
Patient’s serum + drug 0 0 4+ 4+ Not interpretable as a result of autoantibody or alloantibody; adsorb and retest
Patient’s serum + PBS 0 0 4+ 4+
Patient’s serum + C + drug 0 1+ 4+ 4+
Patient’s serum + C + PBS 0 1+ 4+ 4+
RBCs = red blood cells; AHG = antihuman globulin; PBS = phosphate-buffered saline; C = complement; H = hemolysis; — = no cells left; m+ = micro.
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occurring. If both the complement plus drug and complement 
plus PBS tests are positive and the patient’s serum plus drug or 
PBS (without complement added) was not informative, the test 
should be repeated with a new source of complement.
If negative results are obtained using this method but the 
patient’s history warrants further evaluation, use of a different 
concentration of drug (e.g., saturated solution18), wash for the 
antiglobulin test using a solution of drug (e.g., 1 mg/mL29), or 
testing with drug metabolites substituted for the drug solution 
(see later discussion) should be considered.
Titration of Drug Antibodies
Antibody titration against drug-treated RBCs or in the 
presence of drug is of interest when investigating a new drug 
antibody. Antibody titration against drug-treated RBCs should 
be performed if normal serum also reacted with the drug-
treated RBCs for a correct interpretation. For agglutination 
and indirect antiglobulin test titers, dilute the serum in PBS. 
For a hemolysin titer, dilute the serum in fresh normal serum 
(complement source) and read the test only for hemolysis. The 
titer is the reciprocal of the last dilution that reacts 1+ (e.g., a 
serum that reacts 2+ at the dilution 1 in 128, 1+ at 1 in 256, 
and ± at 1 in 512 has a titer of 256).
Test Metabolites of Drug
If there is convincing history incriminating a particular 
drug and the DAT is positive but the drug workup is not 
informative, testing the patient’s serum and eluate against 
metabolites of the drug should be considered. Salama et al.30 
reported detection of antibodies to buthiazide and nomifensine 
only when ex vivo antigen (i.e., serum from volunteers after 
ingestion of the drugs) was tested.30 Antibodies to some 
nonsteroidal anti-inflammatory drugs also have required 
testing in the presence of a urine metabolite for detection.31 
Uncharacterized metabolites can be obtained from serum 
or urine of a patient or volunteer after taking the drug. The 
serum or urine is collected before the drug is taken and at 
various times after ingestion and is substituted for the drug 
solution in testing in the presence of a soluble drug. Previous 
reports may be helpful to determine the appropriate time(s) of 
collection. For diclofenac, the morning void after an evening 
dose of diclofenac (150 mg) was successful.32 The urine is 
centrifuged, and the supernatant is adjusted to pH 6.0 to 8.0, if 
necessary. Purified metabolites are sometimes available from 
drug manufacturers.
Dialysis to Remove Drug From Patient’s Sample
When it is suspected that drug is present in a patient’s 
sample collected when the patient was still receiving the drug 
or shortly thereafter, the blood sample can be dialyzed to 
remove the drug. The sample is placed in dialysis tubing (e.g., 
with a 12,000 to 14,000 molecular weight cutoff [MWCO]) and 
dialyzed in PBS overnight at 4°C.31 Alternatively, Slide-A-Lyzer 
Dialysis Cassettes (Thermo Scientific, Rockford, IL), 2,000 
MWCO, 0.5- to 3.0-mL capacity, work well. A large volume of 
PBS dialysate and two to three changes of the PBS in 24 hours 
will drive the diffusion of drug out of the sample. The dialyzed 
sample is tested with and without drug added. No reactivity 
in the test without drug added (e.g., in the PBS control) and 
reactivity in the test with soluble drug added confirms the 
presence of a drug-dependent antibody.
Unexpected Observations
It should be obvious from the preceding discussion that 
interpreting results of tests for drug antibodies is not always 
easy. We have encountered three serologic problems when 
investigating drug antibodies: (1) normal plasma (e.g., from 
blood donors) directly agglutinates some drug-treated RBCs 
(e.g., cefotetan,19 piperacillin,25 oxaliplatin26); (2) some drugs 
cause nonimmunologic adsorption of protein, resulting in 
positive indirect and direct antiglobulin tests3; and (3) drug 
that is still circulating in a patient’s plasma when the sample 
is collected can result in positive tests without adding drug 
in vitro (e.g., when testing the serum plus PBS control in 
the presence of drug).11 This latter problem has been evident 
in many cases of antibodies to piperacillin; this is most 
disconcerting because serologists are misled to interpret the 
reactivity as warm autoantibody, especially if the eluate is 
also reactive.33,34 Unfortunately, some of these patients with 
antibodies to piperacillin are treated for warm autoimmune 
hemolytic anemia and not immediately taken off the drug that 
is causing the hemolysis.
Another unexpected result is reactivity of the last wash 
control for eluates when testing cefotetan-treated RBCs. 
Increasing the number of washes (e.g., 8 to 12) before preparing 
the eluate does not eliminate the problem.19
In summary, the serologic methods described here 
have been successful in identifying most drug antibodies. 
Including the appropriate controls will help to ensure correct 
interpretation of results. As new drugs come into use, we will 
continue to learn.
Approach to investigating DIIHA
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